[Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].

UNLABELLED Secondary loss of response (initial good response followed by loss of response and flare up) is a frequent event occurring during biological therapy. The aim of this study was to assess loss of efficacy in patients with Crohn's disease treated with infliximab or adalimumab for a year. Secondary goals were to identify clinical or laboratory predictors of loss of response and to evaluate whether the frequency of dose escalation differs in patients receiving infliximab or adalimumab. Data were provided by a computerized database. PATIENTS AND METHODS Sixty-one patients with Crohn's disease achieved remission after induction therapy and received regular maintenance treatment. 35 of them were on infliximab, and 26 on adalimumab therapy. None of the patients treated with infliximab received previous biological therapy, while 10 of the adalimumab-treated patients were naïve to biological therapy. Authors compared the data of patients who relapsed with those who remained in remission and also the characteristics of infliximab-treated patients with adalimumab-naïve patients. Data were analyzed using Chi-square test. Kaplan Meier curve was used to show the time of loss of efficacy. RESULTS Remission was achieved in 70.5%, and response was achieved in 29.5% of the patients after induction. Loss of response occurred in 22 of the 61 patients after a year of therapy. The proportion of remission after induction was significantly lower in patients who lost response vs. those who remained in remission. More patients with sustained remission received immunosuppressive therapy before and during the biological therapy vs. those with loss of response. Loss of response was significantly more frequent and occurred earlier in adalimumab-naive patients vs. infliximab-treated patients. CONCLUSION The need for dose escalation should be calculated in the budget in the majority of patients, especially in adalimumab-treated patients.

[1]  S. Schreiber,et al.  The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? , 2011, The American Journal of Gastroenterology.

[2]  T. Hibi,et al.  Safety and usefulness of balloon endoscopy in Crohn's disease patients with postoperative ileal lesions. , 2011, Journal of Crohn's & colitis.

[3]  A. Zinsmeister,et al.  Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients , 2010, Inflammatory bowel diseases.

[4]  J. Chao,et al.  The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy , 2010, Alimentary pharmacology & therapeutics.

[5]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[6]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[7]  J. Gisbert,et al.  Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.

[8]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.

[9]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[10]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[11]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[12]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[13]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.